MEDIA CONTACTS:Shawn Jain, Whitman-Walker Health, (202) 797-3514; [email protected]Stacey DiLorenzo, George Washington University, (202) 994-8356; [email protected]Kathy Fackelmann, George Washington University, (202) 994-8354; [email protected]
Newswise — Pre-exposure prophylaxis (or PrEP) is the use of the HIV medication Truvada taken daily to prevent HIV infection. The drug was approved for this indication by the FDA in 2012 and recommended for use by certain populations vulnerable to HIV infection by the CDC in May of this year.
Since that May release, there has been a lot of national press on the controversy surrounding its use, and how it best makes sense to make it implement it as a prevention intervention. Issues raised include those of cost, adherence, the potential for less condom use, and increased risk of developing drug-resistant HIV infection.
WHAT:Panel discussion on PrEP for HIV prevention and its role in the HIV epidemic.
WHEN:Monday, September 29 from 6:30-8:30 PM ET
WHO:• Dr. Richard Elion, Director of Research, Whitman-Walker Health• Michael Weinstein, President, AIDS Healthcare Foundation• Dázon Dixon Diallo, Founder/CEO, SisterLove, Inc.• Christopher Chauncey Watson, Clinical Research Site Director, Milken Institute School of Public Health at the George Washington University
WHERE:Milken Institute School of Public HealthFirst Floor Auditorium950 New Hampshire Ave, NWWashington, D.C.
RSVP:To attend the event and/or schedule interviews with panelists please contact Shawn Jain at [email protected]; Kathy Fackelmann at [email protected]; or Stacey DiLorenzo at [email protected]. Note that the event will also be webcast. For information on viewing the webcast, email one of the media contacts.
RSS